Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease
Open Access
- 1 September 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (5), 660-671
- https://doi.org/10.1164/rccm.201912-2384pp
Abstract
Precision medicine is an approach that combines individual clinical characteristics with additional biological information to distinguish between patients with similar diagnoses, with the aim of predicting disease course and treatment response. Biomarkers have an important role in the practical implementation of precision medicine and enrichment of clinical trial populations. For patients with chronic obstructive pulmonary disease, higher blood eosinophil counts, in combination with clinical characteristics, are associated with increased response to corticosteroids and targeted therapies. A single blood eosinophil count cutoff value is not appropriate for identification of potential treatment response, because often a continuous relationship exists between blood eosinophil counts and treatment response. Response also varies with clinical characteristics such as exacerbation risk and current smoking status. Future incorporation of blood eosinophil counts into clinical trials could potentially reduce drug development costs and trial failures. Including blood eosinophil counts as a biomarker in clinical trials will also provide further opportunities to evaluate aspects of eosinophil testing and standardization of methodology and clinical utility. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).This publication has 76 references indexed in Scilit:
- Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variabilitycclm, 2013
- Eosinophils and Disease PathogenesisSeminars in Hematology, 2012
- Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPDRespiration, 2009
- Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbationInternational Journal of Chronic Obstructive Pulmonary Disease, 2009
- Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary diseaseThorax, 2005
- Long-term Repeatability of Induced Sputum Cells and Inflammatory Markers in Stable, Moderately Severe COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthmaThorax, 2002
- Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatabilityRespiratory Medicine, 2001
- Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPDEuropean Respiratory Journal, 2000